Alto Neuroscience Secures $120 Million Private Placement Financing

Alto Neuroscience, Inc. ( (ANRO) ) has shared an update.

On March 16, 2026, Alto Neuroscience, Inc. entered into a securities purchase agreement for a private placement of 2.9 million common shares and pre-funded warrants for 3.1 million additional shares, at $20.00 per share or $19.9999 per warrant. The deal, led by Commodore Capital and joined by several biotech-focused investors, is expected to generate about $120 million in gross proceeds and expand Alto’s board to seven directors.

Alto announced that it intends to use the financing to advance ALTO-207, its fixed-dose pramipexole/ondansetron combination for treatment-resistant depression, through a planned Phase 3 trial and potential New Drug Application submission. The company expects to start a Phase 2b study in the first half of 2026, initiate Phase 3 in early 2027 and, pro forma for the transaction, estimates it would have held roughly $275 million in cash and equivalents as of February 28, 2026, strengthening its ability to complete pivotal development of ALTO-207.

The private placement is structured as a PIPE, with the securities sold in a transaction exempt from registration under U.S. securities laws and supported by a registration rights agreement for subsequent resale. Jefferies, BofA Securities, TD Cowen, Stifel, William Blair and Baird acted as placement agents, while Alto and the agents were advised by Cooley LLP and Latham & Watkins LLP, respectively, underscoring strong Wall Street backing for the company’s precision psychiatry strategy.

The most recent analyst rating on (ANRO) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Alto Neuroscience, Inc. stock, see the ANRO Stock Forecast page.

Spark’s Take on ANRO Stock

According to Spark, TipRanks’ AI Analyst, ANRO is a Neutral.

The score is held down primarily by weak fundamentals typical of a pre-commercial biotech—no meaningful revenue, expanding losses, and significant cash burn—creating ongoing financing risk. This is partly offset by strong technical momentum (price above major moving averages with positive MACD) and a supportive corporate event (a $50M raise to fund clinical progress). Valuation remains constrained by losses and the absence of a dividend.

To see Spark’s full report on ANRO stock, click here.

More about Alto Neuroscience, Inc.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders. Its Precision Psychiatry Platform uses brain biomarkers from EEG, neurocognitive tests, wearable data and other measures to match patients to drug candidates, with a pipeline spanning bipolar depression, major depressive disorder, treatment-resistant depression, schizophrenia and other mental health conditions.

The company’s lead program ALTO-207 is a fixed-dose combination of pramipexole, a dopamine D3-preferring D3/D2 agonist with demonstrated antidepressant effects, and ondansetron, a 5-HT3 antagonist used as an antiemetic. ALTO-207 is designed to enable rapid titration and higher dosing of pramipexole by mitigating dose-limiting side effects and is being developed to address significant unmet need in treatment-resistant depression.

In a randomized, placebo-controlled Phase 2a trial in 32 patients with depression, ALTO-207 met primary and secondary endpoints with significantly greater MADRS improvements versus placebo. Patients reached a mean dose of 4.1 mg per day, and the regimen was well tolerated during maintenance, with an adverse event profile similar to placebo.

Average Trading Volume: 261,199

Technical Sentiment Signal: Buy

Current Market Cap: $691.5M

See more insights into ANRO stock on TipRanks’ Stock Analysis page.